Navigation Links
BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
Date:5/8/2008

alleviation of symptoms are consistent with prior

Phase II study results of the 300mg dose of i.m. peramivir.

-- Reductions in viral shedding and percentage of patients shedding virus

were consistent with the data seen in our previous phase II study.

-- Pharmacokinetic data in the treated population indicate that patients

achieved consistent drug levels, which were similar to those seen in

our previous well-controlled Phase I trial.

BioCryst is continuing development of a more concentrated formulation and plans to test higher doses of i.m. peramivir in the next Phase II study. The doses to be studied in Phase II will be selected based on a planned mid 2008 analysis of the ongoing Phase I study of the more concentrated formulation.

"We are encouraged by the signs of activity of i.m. peramivir and are prepared to move forward and evaluate a higher dose. The consistency seen between the results of our recent clinical trials gives us confidence that i.m. peramivir has the potential to be an effective treatment for influenza," stated Dr. Thomas J. Simon, Interim Chief Medical Officer.

BCX-4208 development update

Following review of a planned interim analysis of the ongoing Phase IIa trial of BCX-4208 in psoriasis, Roche has terminated its license agreement for the development of BCX-4208 for autoimmune diseases and transplant. As a result, BioCryst will regain worldwide rights to BCX-4208. Roche and BioCryst have agreed to complete the ongoing Phase IIa trial. The planned interim analysis showed that BCX-4208 was safe and well-tolerated; clinical efficacy was not demonstrated.

The ongoing Phase IIa trial is a randomized, double blind, placebo controlled, dose ranging study in 66 patients with moderate to severe plaque psoriasis. BCX-4208 is administered once a day for 6 weeks at a dose of either 20mg or 120mg. The primary objectives of this study are to assess the safety, tolerability, an
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
2. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
3. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
4. BioCryst to Present at UBS 2007 Global Life Sciences Conference
5. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
6. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
7. Dendreon Reports First Quarter 2008 Financial Results
8. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Oncothyreon Reports First Quarter 2008 Financial Results
11. iCAD Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015 The UPMC Center for Health ... in the Emerging Leaders in Biosecurity Initiative (ELBI). As ... the field of biosecurity, UPMC has selected 28 US ... array of backgrounds, including biological science, medicine, policy, the ... "With the vision and support of the Defense ...
(Date:3/4/2015)... CALGARY , March 4, 2015 /CNW/ ... that it has completed a collaborative research ... quantitative analytics.  Using Fast Collective Evolution Technology ... dataset including all measurements obtained from each ... Company,s Phase 2 clinical trials ASSERT, SUSTAIN ...
(Date:3/4/2015)... , March 4, 2015 Vegalab announced ... in August of last year. As part of the ... Bon Koo continuing his role as CEO for ... of Vegalab S.A., will work alongside Koo and oversee ... - http://photos.prnewswire.com/prnh/20150303/179218 Koo founded ...
(Date:3/3/2015)... 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: ... diagnostics that target the underlying mechanisms of cancer, today ... ended December 31, 2014. Effective July 17, ... May 31 to December 31. As a result of ... for the quarter and the seven months ended December ...
Breaking Biology Technology:UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... 12 TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ) today ... 2008. For the three-month period, the Company posted,revenue of ... Cash and cash,equivalents totaled $14.3 million at September 30, ... productive as we further,our transition to a development-only company," ...
... CONSHOHOCKEN, Pa., Nov. 12 GEL Interactive,Technologies, a ... Product Director, will be a featured speaker at ... Forum on Defining Appropriate,and Effective Interactions with Thought ... Annual Forum provides a platform for attendees to ...
... Inc.,(Nasdaq: BNVI ) announced today the appointment of ... Weiss is a cardiologist with,expertise in clotting and coagulation ... Institute and the Division of Cardiology at,the University of ... to have Ethan on the scientific advisory board as,we ...
Cached Biology Technology:TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments 2TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments 3TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments 4TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments 5TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments 6TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments 7Cadient Group's GEL Interactive Technologies to Present and Exhibit at CBI's 5th Annual Forum 2Ethan Weiss, M.D., Joins Bionovo's Scientific Advisory Board 2Ethan Weiss, M.D., Joins Bionovo's Scientific Advisory Board 3
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , ... cancer, today announced that Murali Prahalad , Ph.D., president ... Medicine World Conference (PMWC) 2015: Silicon Valley, which is ... Mountain View, Calif. on January 26-28, 2015. ... Come of Age as Biomarkers." Last year, Epic Sciences was ...
(Date:2/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces it ... Conference on January 29 th at 10:30 a.m. ... of NXT-ID will present and host a live Q&A ... and its full suite of biometric technologies. Investors can ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ( ... - A Global Market Overview" report to their offering. ... is to ensure that an individual is who she/he is ... make use of a person,s unique physical characteristics, such as ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... this weeks PLoS Medicine, researchers have found that more ... infectious eye disease trachoma. Six million people most ... the developing world are blind because of the ... that multiple strains of the Chlamydiceae family of bacteria ...
... Hydrogen peroxide, the same mild acid that many people use ... also produced by the body to keep cells healthy. Now, ... how part of this complex process works. Reporting ... by W. Todd Lowther, Ph.D., developed a three-dimensional snapshot of ...
... coalition of 17 organizations, including the National Academy ... the National Science Teachers Association, is calling on ... the promotion of science education, including evolution. According ... issue of The FASEB Journal, the introduction of ...
Cached Biology News:Multiple species of bacteria may cause trachoma: Implications for treatment 2Research explores role of hydrogen peroxide in cell health 2Evolution education is a 'must' says coalition of scientific and teaching organizations 2
... Satellite Thermal Cycler (MBS) is ... for medium to high throughput ... the latest in satellite block ... PC control, resulting in a ...
...
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
CQCS kit for etra KR 4i , (other units)....
Biology Products: